China only recently introduced HPV vaccines, and HPV vaccination is yet to be included in the National Immunization Plan. This article offers an overview of current experience in HPV vaccination in China, including the general background of cervical cancer prevention and control in China, recent advances in HPV vaccination, and major challenges and solutions to HPV vaccination in China. This article found that while current HPV vaccination rate upon full completion was around 3% in China and lower among adolescents, a few advances were under way, such as the exploration of models in which community health service centers serve as the main venue to vaccination, while multiple other channels can be utilized to provide services, as well as the emergence of free vaccination pilots in 2020. Major challenges in HPV vaccination in China included high price and insufficient supply of domestic vaccines, lack of awareness and willingness among the primary target group, and lack of institutional staff capacity and quality and convenient services. This article then made several recommendations to promote HPV vaccination in China, including promoting policy development guided by the WHO elimination strategy, ensuring adequate supply and affordable price of vaccines, improving the quality and coverage of vaccination, strengthening public communication and mobilization, and improving efficiency of vaccine supply through innovative methods.